Prof Stefan Both, PhDHead of Medical Physics
Prof Joseph Deasy, PhDChair of the Department of Medical Physics
Taku Inaniwa, PhDGroup leader NIRS-QST
Prof Yona Keisari, PhDChief Scientific Officer
Prof Eduardo Moros, PhDChief of Medical Physics
Prof Katia Parodi, PhDChair of Medical Physics
Prof Lawrence Pinsky, PhDMoores Professor of Physics
Prof Gabriel Sawakuchi, PhDAssociate Professor (tenured) of Radiation Physics
Dr Suzie Sheehy, PhDAccelerator Physicist
Prof Taiga Yamaya, PhDTeam Leader of Imaging Physics Team
Groningen University Medical Center, Netherlands
Prof Stefan Both, PhD
Head of Medical Physics and Instrumentation in the Department of Radiation Oncology
Stefan Both received his PhD degree from the Babes-Bolyai University, in 2005. His Physicist career started at the Kiricuta Oncology Institute, Romania, in 1996. He immigrated to the US in 2000 and worked in private and academic radiation oncology. In 2008, Dr Both became a faculty member at the University of Pennsylvania, Philadelphia, where he was able to advance treatment programs in conventional radiotherapy, establish and lead the physics residency programs, and spearhead technical advances, including proton therapy. In 2015, he joined Memorial SloanKettering Cancer Center, New York, as an Associate Attending and Lead Physicist.
Currently, Dr. Both is the Professor and Head of Medical Physics and Instrumentation in the Department of Radiation Oncology at the Groningen University Medical Center, Netherlands. He is board certified by the American Board of Radiology in Therapeutic Radiological Physics, a Fellow of the American Association of Physicists in Medicine and an Extraordinary Member of the Dutch Medical Physics Society.
He serves on committees of the American Association of Physicists in Medicine, Particle Therapy Co-Operative Group, Commission on Accreditation of Medical Physics Programs and American Board of Radiology.
Dr. Both has been an invited speaker and committee member at conferences, published over 70 papers in peer reviewed journals, has more than 140 conference contributions, participates to editorial and advisory boards and edited and co-authored books. His main research interests are advanced treatment planning, motion and range uncertainty management, biological guided adaptive radiotherapy and atomization in proton therapy.
Memorial Sloan Kettering Cancer Center, in New York City
Prof Joseph Deasy, PhD
Chair of the Department of Medical Physics and Chief of the Service for Predictive Informatics
I am an attending physicist with expertise in applying statistical modeling to the analysis of large, complex datasets in order to understand the relationship between treatment, patient, and disease characteristics and the probability of local control and normal tissue toxicity. My group’s research has focused specifically on algorithms that can be used to optimize treatment planning dose-distribution characteristics (calculating the best way to deliver increased radiation to the tumor while reducing radiation to surrounding tissue) and modeling the probability of treatment success (tumor eradication) and normal tissue complications as the radiation dose distribution varies.
NIRS-QST Chiba Japan
Taku Inaniwa, PhD
National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST) in Japan
Taku Inaniwa, Ph.D, is a group leader of treatment beam research group at National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST) in Japan. His research focuses on developing dose calculation algorithms and biological models used for charged particle therapy treatment planning. In addition, he is also interested in the development of novel treatment methods.
He has contributed ~100 peer reviewed publications. Three of his first author publications have been selected as Highlights from Physics in Medicine and Biology. He is a member of the international scientific advisory board of the journal. For his works, he has received several national and international awards.
Tel Aviv University, Israel
Prof Yona Keisari, PhD
Professor Yona Keisari
Chief Scientific Officer
Alpha Tau Medical LTD, Tel Aviv, Israel
Department of Clinical Microbiology and Immunology
Sackler Faculty of Medicine, Tel Aviv University, Israel
Member of the Dept. of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Israel, since 1979. Full Professor (2002-2015), Prof. Emeritus since 2015.
Chief Scientific Officer and co-founder of Alpha Tau Medical, Tel Aviv Israel since 2016. Responsible for promoting and organizing clinical trials worldwide and for basic and translational research.
Main research topics:
I. Development of tumor destruction (ablation) treatments of solid metastatic tumors by a unique intratumoral alpha radiation treatment using radium-224 loaded sources (Diffusing alpha-emitters radiation therapy, DaRT).
II. The activation of anti-tumoral immune reactivity by in situ destruction of solid tumors with DaRT and developing immuno-manipulating means to augment such immune responses and achieve improved eradication of metastases.
Co-author of 92 peer reviewed scientific papers, 6 reviews, 5 chapters in books, edited 2 books, and two patents. Deputy editor of “mediators of inflammation” and member of editorial board of 5 other journals. Supervised 17 Ph.D. students and 36 M.Sc. students.
One of the founders and past president of the “Israeli Society for Cancer Research” (ISCR). Since 2015 serve as the treasurer of the “International Cancer Microenvironment Society”. Held a variety of management positions at the Tel Aviv University, and in national and international professional societies, and served as a member of the executive committee of the “European Association for Cancer Research (EACR)” (2013-2015).
H. Lee Moffitt Cancer Center
Prof Eduardo Moros, PhD
After a year at the University of Wisconsin-Madison, he joined the Mallinckrodt Institute of Radiology at Washington University School of Medicine, St. Louis, MO, where he served as Chief of Hyperthermia Physics (1991-2005) and Head of the Research Physics Section (2001-2005). He became an Associate Professor (tenured) in 1999 and a Professor in 2005. Later that year he joined the University of Arkansas for Medical Sciences as Director of the Division of Radiation Physics and Informatics. Since 2011, He has been the Chief of Medical Physics for the Departments of Radiation Oncology and Diagnostic Imaging at the Moffitt Cancer Center and Research Institute, Tampa, FL, an NCI designated comprehensive cancer center.
He is also the director of the CAMPEP-accredited Ph.D. program in Applied Physics with Concentration in Medical Physics, a joint program with the University of South Florida where he is a faculty member in the departments of Physics and Oncological Sciences.
Dr. Moros served as President of the Society for Thermal Medicine (2004-2005), Associate Editor for Medical Physics (2000-2007), Radiation Research (2008-2013) and the International Journal of Hyperthermia (2006-2009). He currently is an Associate Editor of the Journal of Clinical Applied Medical Physics and the Journal of Radiation Oncology. Dr. Moros served as a permanent member of the NIH Radiation Therapeutics and Biology Study Section (RTB 2002-2005). He is an active member of AAPM and ASTRO. Dr. Moros is a diplomate of the American Board of Radiology in Therapeutic Medical Physics (DABR) and a fellow of the AAPM (FAAPM). Dr. Moros’ strength is to collaborate with scientists and clinicians in the application of physics and engineering to facilitate biomedical research and promote translational studies.
He has published more than 185 peer-reviewed articles and has been a principal investigator/co-investigator on multiple research grants from the NIH, other federal agencies, industry, and foundations. He was a recipient of an NIH Challenge Grant in Health and Science Research (RC1) and the J. Eugene Robinson Award. His current research areas are applications of quantitative imaging (e.g., Radiomics, Imaging Habitats), oncologic mathematical modeling and artificial intelligence to personalize and adapt radiation therapy; and radiation dosimetry of targeted alpha-particle therapy for metastatic cancer.
Ludwig-Maximilians-University (LMU) in Munich
Prof Katia Parodi, PhD
Katia Parodi received her Ph.D. in Physics from the University of Dresden, Germany, in 2004. She then worked as a postdoctoral fellow at Massachusetts General Hospital and Harvard Medical School in Boston, USA. In 2006 she returned to Germany as tenured scientist and group leader at the Heidelberg Ion Therapy Center, obtaining in 2009 her Habilitation from the Heidelberg University. Since 2012 she is a full professor and Chair of Medical Physics at the Physics Faculty of the Ludwig-Maximilians-University (LMU) in Munich, where she initiated a dedicated curriculum for Medical Physics within the Physics MSc. She also retained a secondary affiliation with the Heidelberg Ion Therapy Center.
Her main research interests are in high precision image-guided radiotherapy with a special focus on ion beams, from advanced computational modeling to experimental developments and clinical evaluation of novel methods for in-vivo ion range monitoring. Katia Parodi has been invited speaker and committee member at many conferences, and contributed to over 90 publications in peer reviewed journals, more than 150 conference contributions, 5 book
chapters and a couple of patents. For her work she received several national and international recognitions, including the Behnken Berger Award in 2006, the IEEE Bruce Hasegawa Young Investigator Medical Imaging Science Award in 2009 and the AAPM John S. Laughlin Young Scientist in 2015. Since 2015 she is also vice president of the German
Society for Medical Physics (DGMP).
University of Houston
Prof Lawrence Pinsky, PhD
He is a member of the Medipix2, Medipix3 and Medipix4 Collaborations, also at CERN, and is involved in the development of Medipix-based dosimeters and radiation monitors for NASA use on current and future manned missions. He is also working with the Baylor College of Medicine’s Translational Research Institute for Space Health (TRISH) on the development of Medipix-based research instruments for the evaluation of the feasibility of using high
altitude aircraft flights in polar regions as an analog laboratory for Dose Equivalent rates similar to those experienced in Low Earth Orbit (LEO) outside of the South Atlantic Anomaly.
He has a BS in Physics from Carnegie-Mellon University (1968) and an MA (1969) and Ph.D. (1973) in Physics from the University of Rochester. While on active duty with the US Army, he served as a Capt. In the Corps of Engineers at NASA’s then Manned Spacecraft Center in Houston during the Apollo and Skylab projects, where he participated in the first Light Flash Investigations and did Heavy Cosmic Ray Dosimetry for the later Apollo missions.
He is also a patent attorney with a JD and LL.M. in Information and Intellectual Property Law from the University of Houston, as well holding FAA ratings as a multi-engine instrument flight Instructor. He was recently inducted as a Member of the International Academy of Astronautics, and also of the new ICRU committee to consider the setting of standards for the use of solid state dosimeter devices.
The University of Texas MD Anderson Cancer Center
Prof Gabriel Sawakuchi, PhD
Dr Sawakuchi is an Associate Professor (tenured) of Radiation Physics at The University of Texas MD Anderson Cancer Center. He is a board certified medical physicists with clinical work focused on gastrointestinal malignancies. Dr Sawakuchi’s research is at the interface of radiation physics and radiobiology and currently focuses on understanding how radiation-induced DNA damage and repair can be leveraged to combat cancer and to predict radiation response. Dr Sawakuchi’s lab studies how genomic features of the tumor and normal tissue could be used to predict the response of an individual patient to radiation in order to personalize radiotherapy. His lab also studies synergistic combinations of radiation with DNA repair deficiency, via mutation or pharmacological inhibition, to sensitize the tumor and to activate the immune system to combat cancer. At MD Anderson Dr. Sawakuchi co-leads the Biomarker
Initiative at the Division of Radiation Oncology.
University of Oxford University of Melbourne
Dr Suzie Sheehy, PhD
Dr. Suzie Sheehy is a physicist, academic and science communicator who divides her time between her research groups at the University of Oxford (where she is a Royal Society University Research Fellow) and the University of Melbourne (where she is Senior Lecturer). Her research focuses on developing new particle accelerators for future applications in areas such as medicine and energy.
An award-winning public speaker, presenter and science communicator, Suzie is dedicated to sharing science beyond the academic community. She has delivered professional lectures and keynote presentations, written and delivered live shows to tens of thousands of students, is an expert TV presenter of Impossible Engineering for Discovery Channel and in 2018 delivered her first TED talk as part of TEDx Sydney, which has received over 1.4M views – watch it on TED.com.
National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST) in Japan
Prof Taiga Yamaya, PhD
Taiga Yamaya, Ph.D, is a Team Leader of Imaging Physics Team at National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST) in Japan. His research interest is the development of next generation positron emission tomography (PET) systems as well as the development of radiation detectors and image reconstruction algorithms. He obtained his Ph. D degree in 2000.
He has been awarded more than 10 prizes, one of which was the 1 st prize of German Innovation Award (2012). He has accomplished more than 100 peer reviewed publications and more than 50 registered patents. He is also a visiting professor at Chiba University and Yokohama City University. In Yamaya’s laboratory at NIRS-QST, using their core technologies of depth-of-interaction (DOI) measurement, they are developing a new equipment concept of “OpenPET” for joint PET – therapy imaging and a brain-dedicated PET scanner for earlier diagnosis of dementia.